We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+29.29%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$9.47B
AUM Growth
+$451M
(+5%)
Cap. Flow
+$1.13B
Cap. Flow
% of AUM
11.96%
Top 10 Holdings %
Top 10 Hldgs %
21.59%
Holding
903
New
107
Increased
255
Reduced
393
Closed
103
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BPMC
Blueprint Medicines
BPMC
|
+$51.9M |
| 2 |
Merck
MRK
|
+$50.9M |
| 3 |
Danaher
DHR
|
+$45.3M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$37.8M |
| 5 |
JD.com
JD
|
+$37.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$103M |
| 2 |
Alibaba
BABA
|
+$98.6M |
| 3 |
Salesforce
CRM
|
+$62.5M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$59.4M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
+$48.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 34.61% |
| 2 | Technology | 20.94% |
| 3 | Consumer Discretionary | 8.9% |
| 4 | Financials | 8.59% |
| 5 | Communication Services | 7.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
LM
226
DELISTED
Legg Mason, Inc.
LM
| $9.11M | 0.1% |
+183,184
| New | +$9.1M |
|
227
Booking.com
BKNG
$154B
| $9.08M | 0.1% |
142,600
-76,525
| -35% | -$4.66M |
|
228
ResMed
RMD
$30.3B
| $9M | 0.1% |
46,885
+35,351
| +306% | +$5.78M |
|
229
Hershey
HSY
$37.2B
| $8.92M | 0.09% |
68,844
+43,404
| +171% | +$5.84M |
|
230
DuPont de Nemours
DD
$19B
| $8.91M | 0.09% |
133,673
-44,149
| -25% | -$2.58M |
|
231
Colgate-Palmolive
CL
$74.2B
| $8.89M | 0.09% |
121,296
-35,946
| -23% | -$2.55M |
|
|
EIDX
232
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| $8.85M | 0.09% |
185,721
+13,966
| +8% | +$650K |
|
233
Goldman Sachs
GS
$305B
| $8.82M | 0.09% |
44,632
+39,514
| +772% | +$7.42M |
|
|
CLVS
234
DELISTED
Clovis Oncology, Inc.
CLVS
| $8.77M | 0.09% |
1,298,450
+298,535
| +30% | +$2.26M |
|
|
AERI
235
DELISTED
Aerie Pharmaceuticals
AERI
| $8.73M | 0.09% |
591,800
-78,000
| -12% | -$1.15M |
|
236
Tetra Tech
TTEK
$8.7B
| $8.7M | 0.09% |
493,060
+241,195
| +96% | +$3.66M |
|
237
Zions Bancorporation
ZION
$10.1B
| $8.68M | 0.09% |
255,203
-158,535
| -38% | -$5.02M |
|
|
KYNB
238
Kyntra Bio
KYNB
$28.2M
| $8.67M | 0.09% |
8,556
-700
| -8% | -$650K |
|
239
SolarEdge
SEDG
$2.44B
| $8.49M | 0.09% |
61,148
+15,338
| +33% | +$1.88M |
|
|
MOR
240
DELISTED
MorphoSys AG American Depositary Shares
MOR
| $8.45M | 0.09% |
266,750
+159,044
| +148% | +$4.64M |
|
241
Bilibili
BILI
$7.56B
| $8.41M | 0.09% |
+181,500
| New | +$5.89M |
|
242
Idexx Laboratories
IDXX
$44.9B
| $8.32M | 0.09% |
25,214
+18,061
| +252% | +$5.23M |
|
243
Mondelez International
MDLZ
$80.2B
| $8.22M | 0.09% |
160,850
-136,111
| -46% | -$6.99M |
|
|
KSU
244
DELISTED
Kansas City Southern
KSU
| $8.16M | 0.09% |
54,647
+45,672
| +509% | +$6.42M |
|
245
Kinder Morgan
KMI
$70.3B
| $8.16M | 0.09% |
537,712
-213,261
| -28% | -$3.24M |
|
246
Stryker
SYK
$133B
| $8.08M | 0.09% |
44,860
-11,439
| -20% | -$2.11M |
|
247
Insmed
INSM
$22.6B
| $8.04M | 0.08% |
+292,000
| New | +$6.92M |
|
|
ALLK
248
DELISTED
Allakos
ALLK
| $8.04M | 0.08% |
111,872
+61,872
| +124% | +$4.15M |
|
249
AutoZone
AZO
$50.9B
| $7.95M | 0.08% |
7,045
+4,648
| +194% | +$4.9M |
|
250
Power Integrations
POWI
$3.3B
| $7.93M | 0.08% |
134,274
+56,396
| +72% | +$2.96M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2020 Portfolio in Review
As of Q2 2020, Candriam SCA held 903 positions worth $9.47B, up 5% from $9.02B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Candriam SCA deployed $1.13B of net new capital in Q2 2020, opening 107 new positions and adding to 255 existing holdings. Its largest new stake was JD.com: 744,410 shares worth $44.8M.
By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 31% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $103M trimmed.
- Candriam SCA's largest Q2 2020 buy was JD.com: 744,410 shares worth $44.8M.
- Candriam SCA added most to Blueprint Medicines in Q2 2020, an estimated $51.9M increase.
- Candriam SCA's biggest Q2 2020 reduction was Regeneron Pharmaceuticals, cutting an estimated $103M.
- Candriam SCA fully exited Salesforce in Q2 2020, selling an estimated $62.5M.
- Candriam SCA's ten largest holdings make up 22% of its $9.47B portfolio in Q2 2020.
- Candriam SCA opened 107 new positions and closed 103 in Q2 2020.
- Candriam SCA's portfolio value rose 5% quarter-over-quarter to $9.47B.
Based on Candriam SCA's 13F filing for Q2 2020, filed 23 Jul 2020.